Digital Therapeutics Endometriosis Global Market Report 2025

The digital therapeutics endometriosis market size has grown exponentially in recent years. It will grow from $1.39 billion in 2024 to $1.7 billion in 2025 at a compound annual growth rate (CAGR) of 22.6%. The growth during the historic period can be attributed to the rising prevalence of endometriosis, increasing awareness of digital therapeutics, growing demand for noninvasive treatment options, expansion of telehealth platforms, and the increasing adoption of mobile health applications.

The digital therapeutics endometriosis market size is expected to see exponential growth in the next few years. It will grow to $3.81 billion in 2029 at a compound annual growth rate (CAGR) of 22.3%. The growth in the forecast period can be attributed to rising patient acceptance of digital therapies, increasing integration of artificial intelligence in treatment solutions, growing government initiatives supporting digital health adoption, expanding insurance coverage for digital therapeutics, and strengthening collaborations between pharmaceutical and technology companies. Key trends during the forecast period include innovations in wearable monitoring technologies, advancements in AI-powered symptom tracking, ongoing research and development in digital biomarkers, expansion of cloud-based health data platforms, and the integration of telemedicine with digital therapeutics.

The increasing adoption of smartphones is expected to drive the growth of the digital therapeutics endometriosis market in the coming years. Smartphones are portable devices that combine communication, internet access, and computing capabilities in one unit. Their adoption is rising due to increasing internet penetration, which allows users to conveniently access online services, social media, and digital entertainment. The widespread use of smartphones supports digital therapeutics for endometriosis by offering users seamless and continuous access to personalized therapeutic applications, enabling real-time symptom tracking, data monitoring, and evidence-based treatment guidance from anywhere. For example, in February 2023, according to a report by Uswitch Limited, a UK-based comparison and switching service provider, there were 71.8 million active mobile connections in 2022, and by 2025, it is projected that 95 percent of the 68.3 million people in the UK will own smartphones. Hence, the growing adoption of smartphones is contributing to the expansion of the digital therapeutics endometriosis market.

Major companies in the digital therapeutics endometriosis market are engaging in strategic collaborations to accelerate innovation and enhance patient support by combining expertise and resources. Such collaborations involve multiple organizations working together to achieve shared goals, pool resources, or leverage each other’s strengths. For example, in March 2024, Endometriosis Australia, a nationally accredited charity based in Australia, collaborated with CHARLI, an Australia-based digital health company, to launch a transformative platform designed to assist thousands of Australians affected by endometriosis. This collaboration led to the creation of an app developed by healthcare professionals and consumers. The app uses AI technology to help women monitor menstruation, fertility, sexual health, pregnancy, and peri/menopause, as well as detect pain and potential conditions such as endometriosis. In partnership with Endometriosis Australia, the initiative aims to support one in seven Australians affected by the condition by facilitating faster diagnosis and easier access to care.

In March 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based research and development-focused pharmaceutical company, partnered with Biofourmis to advance AI-driven digital therapeutics for endometriosis-related pain management. Through this partnership, the companies aim to develop and implement digital solutions that objectively measure and manage pain in individuals with endometriosis, thereby improving treatment outcomes and overall quality of life. Biofourmis, a US-based digital therapeutics company, specializes in developing digital tools for assessing and managing pain associated with endometriosis.

Major players in the digital therapeutics endometriosis market are Bayer AG, Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Luna Endoscore, Chugai Pharmaceutical Co. Ltd., Sword health inc., Charli, Maven Clinic Co., Flo Health Inc., Hinge Health Inc., PrecisionLife Ltd., TiumBio, EpicentRx Inc., Syrona Health, Matilda Health Care, ELANZA Wellness Inc., iCareBetter Inc., Endocare Clinic Fz LLc, Herabiotech, Ziwig Biotech, and Hera Biotech Inc.

North America was the largest region in the digital therapeutics endometriosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in digital therapeutics endometriosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The digital therapeutics endometriosis market research report is one of a series of new reports that provides digital therapeutics endometriosis market statistics, including digital therapeutics endometriosis industry global market size, regional shares, competitors with a digital therapeutics endometriosis market share, detailed digital therapeutics endometriosis market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics endometriosis industry. This digital therapeutics endometriosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digital therapeutics for endometriosis are clinically validated digital health solutions that utilize technology and data-driven approaches to effectively manage the condition. These therapeutics are developed using scientific research and behavioral science to provide personalized, evidence-based treatment programs. They aim to address the physical, emotional, and lifestyle challenges associated with endometriosis while complying with regulatory standards for safety and clinical efficacy.

The main product types of digital therapeutics for endometriosis include software, devices, and services. Software refers to digital platforms, programs, and mobile applications designed to deliver therapeutic interventions and healthcare management solutions. It offers deployment options such as on-premises and cloud-based and is applied for pain management, symptom tracking, fertility management, education, and awareness, among others. These are used by various end users, including hospitals and clinics, homecare settings, research institutes, and others.

The countries covered in the digital therapeutics endometriosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The digital therapeutics endometriosis market consists of revenues earned by entities by providing services such as personalized treatment programs, hormonal health management, teleconsultation support, and mental health support. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics endometriosis market also includes sales of smart ring monitors, implantable sensor devices, wireless hormone monitoring biosensor, and wearable sleep tracker. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.